These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1152 related items for PubMed ID: 17359492

  • 1. Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease.
    Mela F, Marti M, Dekundy A, Danysz W, Morari M, Cenci MA.
    J Neurochem; 2007 Apr; 101(2):483-97. PubMed ID: 17359492
    [Abstract] [Full Text] [Related]

  • 2. Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease.
    Kobylecki C, Cenci MA, Crossman AR, Ravenscroft P.
    J Neurochem; 2010 Jul; 114(2):499-511. PubMed ID: 20456008
    [Abstract] [Full Text] [Related]

  • 3. Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease.
    Dekundy A, Pietraszek M, Schaefer D, Cenci MA, Danysz W.
    Brain Res Bull; 2006 Apr 14; 69(3):318-26. PubMed ID: 16564428
    [Abstract] [Full Text] [Related]

  • 4. L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia.
    Lindgren HS, Andersson DR, Lagerkvist S, Nissbrandt H, Cenci MA.
    J Neurochem; 2010 Mar 14; 112(6):1465-76. PubMed ID: 20050978
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
    Johnston TH, Fox SH, McIldowie MJ, Piggott MJ, Brotchie JM.
    J Pharmacol Exp Ther; 2010 Jun 14; 333(3):865-73. PubMed ID: 20231306
    [Abstract] [Full Text] [Related]

  • 7. Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease.
    Francardo V, Recchia A, Popovic N, Andersson D, Nissbrandt H, Cenci MA.
    Neurobiol Dis; 2011 Jun 14; 42(3):327-40. PubMed ID: 21310234
    [Abstract] [Full Text] [Related]

  • 8. Investigation of the antidyskinetic site of action of metabotropic and ionotropic glutamate receptor antagonists. Intracerebral infusions in 6-hydroxydopamine-lesioned rats with levodopa-induced dyskinesia.
    Maranis S, Stamatis D, Tsironis C, Konitsiotis S.
    Eur J Pharmacol; 2012 May 15; 683(1-3):71-7. PubMed ID: 22410193
    [Abstract] [Full Text] [Related]

  • 9. Amantadine attenuates levodopa-induced dyskinesia in mice and rats preventing the accompanying rise in nigral GABA levels.
    Bido S, Marti M, Morari M.
    J Neurochem; 2011 Sep 15; 118(6):1043-55. PubMed ID: 21740438
    [Abstract] [Full Text] [Related]

  • 10. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
    Muñoz A, Li Q, Gardoni F, Marcello E, Qin C, Carlsson T, Kirik D, Di Luca M, Björklund A, Bezard E, Carta M.
    Brain; 2008 Dec 15; 131(Pt 12):3380-94. PubMed ID: 18952677
    [Abstract] [Full Text] [Related]

  • 11. A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease.
    Johnston TH, Lee J, Gomez-Ramirez J, Fox SH, Brotchie JM.
    Exp Neurol; 2005 Feb 15; 191(2):243-50. PubMed ID: 15649479
    [Abstract] [Full Text] [Related]

  • 12. Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia.
    Kobylecki C, Crossman AR, Ravenscroft P.
    Exp Neurol; 2013 Sep 15; 247():476-84. PubMed ID: 23360800
    [Abstract] [Full Text] [Related]

  • 13. The selective D(3) receptor antagonist, S33084, improves parkinsonian-like motor dysfunction but does not affect L-DOPA-induced dyskinesia in 6-hydroxydopamine hemi-lesioned rats.
    Mela F, Millan MJ, Brocco M, Morari M.
    Neuropharmacology; 2010 Feb 15; 58(2):528-36. PubMed ID: 19733554
    [Abstract] [Full Text] [Related]

  • 14. A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function.
    Lundblad M, Picconi B, Lindgren H, Cenci MA.
    Neurobiol Dis; 2004 Jun 15; 16(1):110-23. PubMed ID: 15207268
    [Abstract] [Full Text] [Related]

  • 15. Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling.
    Rylander D, Recchia A, Mela F, Dekundy A, Danysz W, Cenci MA.
    J Pharmacol Exp Ther; 2009 Jul 15; 330(1):227-35. PubMed ID: 19357321
    [Abstract] [Full Text] [Related]

  • 16. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
    Yang X, Zhao H, Shi H, Wang X, Zhang S, Zhang Z, Zu J, Zhang W, Shen X, Cui G, Hua F.
    Exp Neurol; 2015 Sep 15; 271():168-74. PubMed ID: 26001615
    [Abstract] [Full Text] [Related]

  • 17. Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats.
    Carta M, Lindgren HS, Lundblad M, Stancampiano R, Fadda F, Cenci MA.
    J Neurochem; 2006 Mar 15; 96(6):1718-27. PubMed ID: 16539687
    [Abstract] [Full Text] [Related]

  • 18. A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys.
    Rylander D, Iderberg H, Li Q, Dekundy A, Zhang J, Li H, Baishen R, Danysz W, Bezard E, Cenci MA.
    Neurobiol Dis; 2010 Sep 15; 39(3):352-61. PubMed ID: 20452425
    [Abstract] [Full Text] [Related]

  • 19. Chronic SKF83959 induced less severe dyskinesia and attenuated L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.
    Zhang H, Ma L, Wang F, Chen J, Zhen X.
    Neuropharmacology; 2007 Jul 15; 53(1):125-33. PubMed ID: 17553535
    [Abstract] [Full Text] [Related]

  • 20. Alterations in cortical and basal ganglia levels of opioid receptor binding in a rat model of l-DOPA-induced dyskinesia.
    Johansson PA, Andersson M, Andersson KE, Cenci MA.
    Neurobiol Dis; 2001 Apr 15; 8(2):220-39. PubMed ID: 11300719
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 58.